KIR3DL1 and neoplasm: However, since HER2 expression can be heterogeneously expressed within one tumor or be downregulated in response to trastuzumab treatment [33], KIR-ligand-mismatched NK cells may also be advantageous for HER2-positive patients treated with trastuzumab.